Prosecution Insights
Prosecution Insights
2 pending office actions • 0 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Vernalis (R&D) Ltd. currently has 2 pending office actions. These actions are assigned to 2 distinct examiners, meaning each pending matter is being reviewed by a different individual. The data shows 0 distinct art units, indicating the filings are not currently categorized within specific administrative divisions.
PECKHAM, RICHARD GRANT is the busiest examiner for this portfolio, holding 1 pending office action. Since PECKHAM, RICHARD GRANT and the other distinct examiner each have 1 action, the workload is distributed across the entire examiner pool. Success in the 2 pending office actions will depend on addressing the specific requirements of both PECKHAM, RICHARD GRANT and the other examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18894074 | CRYSTALLINE FORMS OF A MCL-1 INHIBITOR, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PECKHAM, RICHARD GRANT | — |
| 18816347 | HYDROGEN SULFATE SALT OF A BCL-2 INHIBITOR, RELATED CRYSTALLINE FORM, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | WHITE, DAWANNA SHAR-DAY | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18894074 | CRYSTALLINE FORMS OF A MCL-1 INHIBITOR, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PECKHAM, RICHARD GRANT | — | §112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18816347 | HYDROGEN SULFATE SALT OF A BCL-2 INHIBITOR, RELATED CRYSTALLINE FORM, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | WHITE, DAWANNA SHAR-DAY | — | §103§112DP | Non-Final OA | — | Pending | Aug 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial